▶ 調査レポート

急性リンパ性/リンパ芽球性白血病(ALL)治療薬の世界市場:市場規模・現状・予測

• 英文タイトル:Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, Status and Forecast 2019-2025

QYResearchが調査・発行した産業分析レポートです。急性リンパ性/リンパ芽球性白血病(ALL)治療薬の世界市場:市場規模・現状・予測 / Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size, Status and Forecast 2019-2025 / QYR9ST05752資料のイメージです。• レポートコード:QYR9ST05752
• 出版社/出版日:QYResearch / 2019年9月2日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、96ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
※当調査レポートでは、急性リンパ性/リンパ芽球性白血病(ALL)治療薬の世界市場について調査・分析し、急性リンパ性/リンパ芽球性白血病(ALL)治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別(ハイパー-CVADレジメン、リンカーレジメン、ヌクレオシド代謝阻害剤(クロラール及びネララビン))、用途別(小児、大人)、地域別(北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米)に区分して市場規模を算出しました。


・レポートの概要
・世界の急性リンパ性/リンパ芽球性白血病(ALL)治療薬市場動向
・主要企業別マーケットシェア
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の種類別市場規模2014-2019
(ハイパー-CVADレジメン、リンカーレジメン、ヌクレオシド代謝阻害剤(クロラール及びネララビン))
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の用途別市場規模2014-2019
(小児、大人)
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の北米市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬のヨーロッパ市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の中国市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の日本国内市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の東南アジア市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬のインド市場:主要企業・種類別/用途別市場規模
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の中南米市場:主要企業・種類別/用途別市場規模
・主要企業のプロフィール
(AMGEN, INC、BRISTOL-MYERS SQUIBB COMPANY、ERYTECH PHARMA、LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)、NOVARTIS AG、PFIZER, INC、RARE DISEASE THERAPEUTICS, INC、SANOFI、SPECTRUM PHARMACEUTICALS, INC、TAKEDA PHARMACEUTICAL COMPANY LIMITED)
・急性リンパ性/リンパ芽球性白血病(ALL)治療薬の市場規模予測2019-2025
(種類別、用途別、地域別市場予測)
・アナリストの観点・結論
...

Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body.ALL develops in bone marrow and quickly invades other parts of the body including the liver, spleen, lymph nodes, liver, central nervous system, spleen, central nervous system, and the blood. Symptoms can be non-specific and may include feeling weak and tired, paler skin, bruises, frequent and severe bleeding gums, nose bleeds; weight loss, shortness of breath, and loss of appetite. Various types of therapeutics are used for ALL treatment. Chemotherapy is one of the major therapeutics used for ALL treatment.
In 2018, the global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
AMGEN, INC
BRISTOL-MYERS SQUIBB COMPANY
ERYTECH PHARMA
LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
NOVARTIS AG
PFIZER, INC
RARE DISEASE THERAPEUTICS, INC
SANOFI
SPECTRUM PHARMACEUTICALS, INC
TAKEDA PHARMACEUTICAL COMPANY LIMITED

Market segment by Type, the product can be split into
Hyper-CVAD Regimen
Linker Regimen
Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
Targeted Drugs & Immunotherapy
CALGB 8811 Regimen
Oncaspar

Market segment by Application, split into
Pediatrics
Adults

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

レポート目次

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Hyper-CVAD Regimen
1.4.3 Linker Regimen
1.4.4 Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
1.4.5 Targeted Drugs & Immunotherapy
1.4.6 CALGB 8811 Regimen
1.4.7 Oncaspar
1.5 Market by Application
1.5.1 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application (2019-2025)
1.5.2 Pediatrics
1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size
2.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Growth Trends by Regions
2.2.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Regions (2019-2025)
2.2.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by by Players
3.1.1 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue by by Players (2014-2019)
3.1.2 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share by by Players (2014-2019)
3.1.3 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players Head office and Area Served
3.3 Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product/Solution/Service
3.4 Date of Enter into Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type (2014-2019)
4.2 Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application (2014-2019)

5 North America
5.1 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
5.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in North America
5.3 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
5.4 North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

6 Europe
6.1 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
6.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in Europe
6.3 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
6.4 Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

7 China
7.1 China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
7.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in China
7.3 China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
7.4 China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

8 Japan
8.1 Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
8.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in Japan
8.3 Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
8.4 Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
9.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
9.4 Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

10 India
10.1 India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
10.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in India
10.3 India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
10.4 India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size (2014-2019)
11.2 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Players in Central & South America
11.3 Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type
11.4 Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application

12 International Players Profiles
12.1 AMGEN, INC
12.1.1 AMGEN, INC Company Details
12.1.2 Company Description and Business Overview
12.1.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.1.4 AMGEN, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019))
12.1.5 AMGEN, INC Recent Development
12.2 BRISTOL-MYERS SQUIBB COMPANY
12.2.1 BRISTOL-MYERS SQUIBB COMPANY Company Details
12.2.2 Company Description and Business Overview
12.2.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.2.4 BRISTOL-MYERS SQUIBB COMPANY Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.2.5 BRISTOL-MYERS SQUIBB COMPANY Recent Development
12.3 ERYTECH PHARMA
12.3.1 ERYTECH PHARMA Company Details
12.3.2 Company Description and Business Overview
12.3.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.3.4 ERYTECH PHARMA Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.3.5 ERYTECH PHARMA Recent Development
12.4 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.)
12.4.1 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Company Details
12.4.2 Company Description and Business Overview
12.4.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.4.4 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.4.5 LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Recent Development
12.5 NOVARTIS AG
12.5.1 NOVARTIS AG Company Details
12.5.2 Company Description and Business Overview
12.5.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.5.4 NOVARTIS AG Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.5.5 NOVARTIS AG Recent Development
12.6 PFIZER, INC
12.6.1 PFIZER, INC Company Details
12.6.2 Company Description and Business Overview
12.6.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.6.4 PFIZER, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.6.5 PFIZER, INC Recent Development
12.7 RARE DISEASE THERAPEUTICS, INC
12.7.1 RARE DISEASE THERAPEUTICS, INC Company Details
12.7.2 Company Description and Business Overview
12.7.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.7.4 RARE DISEASE THERAPEUTICS, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.7.5 RARE DISEASE THERAPEUTICS, INC Recent Development
12.8 SANOFI
12.8.1 SANOFI Company Details
12.8.2 Company Description and Business Overview
12.8.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.8.4 SANOFI Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.8.5 SANOFI Recent Development
12.9 SPECTRUM PHARMACEUTICALS, INC
12.9.1 SPECTRUM PHARMACEUTICALS, INC Company Details
12.9.2 Company Description and Business Overview
12.9.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.9.4 SPECTRUM PHARMACEUTICALS, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.9.5 SPECTRUM PHARMACEUTICALS, INC Recent Development
12.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.10.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED Company Details
12.10.2 Company Description and Business Overview
12.10.3 Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Introduction
12.10.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
12.10.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Key Market Segments
Table Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Covered
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Hyper-CVAD Regimen Figures
Table Key Players of Hyper-CVAD Regimen
Figuer Linker Regimen Figures
Table Key Players of Linker Regimen
Figuer Nucleoside Metabolic Inhibitors (Clolar and Nelarabine) Figures
Table Key Players of Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
Figuer Targeted Drugs & Immunotherapy Figures
Table Key Players of Targeted Drugs & Immunotherapy
Figuer CALGB 8811 Regimen Figures
Table Key Players of CALGB 8811 Regimen
Figuer Oncaspar Figures
Table Key Players of Oncaspar
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application in 2018 & 2025
Figure Pediatrics Case Studies
Figure Adults Case Studies
Figure Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Report Years Considered
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Regions 2014-2019
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Regions 2014-2019
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue by by Players (2014-2019) (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by by Players (2014-2019)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by by Players in 2018
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Product/Solution/Service
Table Date of Enter into Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Share by Type (2014-2019)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Share by Application (2014-2019)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue Market Share by Application in 2018
Figure North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table North America Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table North America Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Figure Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share (2018-2019)
Table Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Type 2014-2019
Table Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Share by Application 2014-2019
Table AMGEN, INC Company Details
Table AMGEN, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure AMGEN, INC Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table AMGEN, INC Recent Development
Table BRISTOL-MYERS SQUIBB COMPANY Company Details
Table BRISTOL-MYERS SQUIBB COMPANY Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure BRISTOL-MYERS SQUIBB COMPANY Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table BRISTOL-MYERS SQUIBB COMPANY Recent Development
Table ERYTECH PHARMA Company Details
Table ERYTECH PHARMA Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure ERYTECH PHARMA Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table ERYTECH PHARMA Recent Development
Table LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Company Details
Table LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.) Recent Development
Table NOVARTIS AG Company Details
Table NOVARTIS AG Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure NOVARTIS AG Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table NOVARTIS AG Recent Development
Table PFIZER, INC Company Details
Table PFIZER, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure PFIZER, INC Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table PFIZER, INC Recent Development
Table RARE DISEASE THERAPEUTICS, INC Company Details
Table RARE DISEASE THERAPEUTICS, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure RARE DISEASE THERAPEUTICS, INC Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table RARE DISEASE THERAPEUTICS, INC Recent Development
Table SANOFI Company Details
Table SANOFI Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure SANOFI Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table SANOFI Recent Development
Table SPECTRUM PHARMACEUTICALS, INC Company Details
Table SPECTRUM PHARMACEUTICALS, INC Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure SPECTRUM PHARMACEUTICALS, INC Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table SPECTRUM PHARMACEUTICALS, INC Recent Development
Table TAKEDA PHARMACEUTICAL COMPANY LIMITED Company Details
Table TAKEDA PHARMACEUTICAL COMPANY LIMITED Revenue in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business 2014-2019 (Million US$)
Figure TAKEDA PHARMACEUTICAL COMPANY LIMITED Revenue Growth Rate in Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Business (2014-2019)
Table TAKEDA PHARMACEUTICAL COMPANY LIMITED Recent Development
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Share by Regions in 2025
Figure North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Product (2019-2025)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Product in 2025
Table Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application (2019-2025)
Figure Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources